Request Clinical Starter Kits for Your Patients Today! Request Now

 ENDUR ACIN Wax Matrix Niacin Research STUDIES

Study shows ENDUR-ACIN® improves lipid profiles in patients with dyslipidemia, while “flush free” niacin has no effect

Highlights ENDUR-ACIN® (1,500 mg/day) significantly improves lipid profiles in patients with mild-to-moderate dyslipidemia. ENDUR-ACIN® shows an intermediate release and absorption rate over 6 hours. Inositol hexanicotinate (so-called flush-free niacin) shows...
on February 25, 2020

Long-term ENDUR-ACIN® treatment is a safe, effective treatment for dyslipidemia, study shows

Highlights Long-term ENDUR-ACIN® treatment lower LDL cholesterol by 16% Effective dosage is 1,500 mg/day for 38 weeks Excellent treatment compliance with 79% of subjects completing study Possible synergistic effect with...
on February 25, 2020

Extended-release nicotinic acid significantly lowers lipoprotein(a) in patients with heart disease or diabetes, meta-analysis shows

Highlights Meta-analysis includes 14 randomized, placebo-controlled, clinical trials with over 9,000 participants Study dosages of extended-release nicotinic acid range from 1,000 to 3,000 mg/day; study durations, from 8 to 26 weeks A...
on February 25, 2020

ENDUR-ACIN® treatment is especially beneficial in older patients with dyslipidemia, study shows

Highlights A comparison of ENDUR-ACIN® therapy in younger vs. older (50-70 years) patients with dyslipidemia Effective treatment, ENDUR-ACIN® (1,500-2,000 mg/day) for 8 weeks Blood lipid profiles significantly improve, older patients...
on February 25, 2020

ENDUR-ACIN® significantly improves blood cholesterol profiles in patient with dyslipidemia, study shows

Highlights Comparison of different ENDUR-ACIN® protocols (1,000-2,000 mg/day) over 20-week period 1,500 mg/day protocol is most effective and best tolerated with 96% adherence. Significant reductions in LDL cholesterol (-26%) and total-to-HDL cholesterol ratio...
on February 25, 2020